Aarti Pharmalabs Files Q1 FY27 Investor Presentation
Aarti Pharmalabs Limited released its Q1 FY27 investor presentation. Standalone revenue was ₹5,346 million, with EBITDA at ₹1,327 million (24.82% margin). Consolidated revenue was ₹5,358 million, with EBITDA at ₹1,326 million (24.75% margin). PAT stood at ₹713 million standalone and ₹761 million consolidated. The company targets 15-18% Revenue & EBITDA CAGR and plans ₹149 crore capex for Atali Block 2.
The announcement includes detailed financial results for the quarter, a positive future outlook with CAGR targets, and significant capital expenditure plans, all of which are material information for investors.
The company reported significant year-on-year growth in revenue and profit for Q1 FY27, alongside a positive future outlook and strategic capex plans, indicating strong performance and growth prospects.
Aarti Pharmalabs Limited has submitted its Q1 FY27 Results Presentation to the stock exchanges.
The presentation, dated August 2026, provides a comprehensive overview of the company's performance and strategic initiatives. It highlights Aarti Pharmalabs' position as a leading manufacturer of generic APIs, Xanthine derivatives, and a player in CDMO/CMO services. The company boasts over 220 products, 63 patents filed, and 7 manufacturing units, including 3 USFDA-approved facilities. It holds a 15-20% global market share in Xanthine derivatives and serves over 500 global clients across more than 50 export countries.
Financially, for Q1 FY27, the company reported standalone operational revenue of ₹5,346 million and EBITDA of ₹1,327 million, with an EBITDA margin of 24.82%. Consolidated operational revenue stood at ₹5,358 million with EBITDA at ₹1,326 million and an EBITDA margin of 24.75%. Profit After Tax (PAT) for Q1 FY27 was ₹713 million on a standalone basis and ₹761 million on a consolidated basis, showing significant year-on-year growth.
The company provided a future outlook, targeting a 15-18% Revenue and EBITDA CAGR over the next 3-4 years. It also announced a brownfield capex of approximately ₹149 crore for Atali Block 2, with an estimated capacity of 405 KL, targeted for commercialization by H2FY28, primarily for CDMO/CMO projects. R&D investment in FY27 is being initiated towards TIDES (Peptides & Oligonucleotides) to expand portfolio capabilities.
What to do with a filing like this
Aarti Pharmalabs Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarti Pharmalabs Limited. Read the original for the full detail.